New typhoid conjugate vaccines offer important advantages over prior vaccines, including the ability to protect young children, longer lasting protection, and the potential to be a part of routine immunization of infants.

This past weekend, leaders of the world’s major economies gathered in Hamburg, Germany, for this year’s G20 Summit. Among the issues on the agenda: safeguarding against health crises and strengthening health systems.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

This article was originally posted on the DSW Blog.

By the Dengue Vaccine Initiative

During the month of October, END7 student supporters are celebrating NTD Success Stories — spreading the exciting news that many countries around the world have already made incredible progress towards the control and elimination of some NTDs. In recent weeks, there have been many new successes to celebrate.
Dr. Sazaly has been involved with dengue research for over 20 years and has also maintained strong research interest in emerging infectious diseases. His interest in dengue, in particular, is rooted in its knowledge gaps: “it is a fascinating disease needing a lot more research to take on.” In an interview with DVI, Dr. Sazaly shares more on his views of dengue prevention and control and needs in the dengue research field.

This blog was originally published by the Dengue Vaccine Initiative.

Pages